Výsledky vyhledávání

Akademický článek

Clinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy

Autor: Zheng Y, Yu T, Mackey RH, Gayle JA, Wassel CL, Phatak H, Kim R

Publikováno v: ClinicoEconomics and Outcomes Research, Vol Volume 13, Pp 213-226 (2021)

Ying Zheng,1 Ting Yu,2 Rachel H Mackey,3,4 Julie A Gayle,3 Christina L Wassel,3 Hemant Phatak,1 Ruth Kim5 1 EMD Serono, Inc., Rockland, USA; An Affiliate of Merck KGaA, Darmstadt, Germany; 2Global Medical Affairs, EMD Serono, Inc., Rockland, MA, USA;

Externí odkaz: https://doaj.org/article/523e878046ea4f48a8e7e86cfcbcc899

Zobrazit plný text záznamu

Akademický článek

Treatment Sequencing Patterns in Patients with Metastatic Urothelial Cancer Treated in the Community Practice Setting in the United States: SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR)

Autor: Doshi GK, Bhanegaonkar A, Kearney M, Bharmal M, Cislo P, Kim R, Boyd M, Aguilar KM, Phatak H

Publikováno v: ClinicoEconomics and Outcomes Research, Vol Volume 12, Pp 645-656 (2020)

Gurjyot K Doshi,1 Abhijeet Bhanegaonkar,2 Mairead Kearney,3 Murtuza Bharmal,2 Paul Cislo,4 Ruth Kim,4 Marley Boyd,5 Kathleen M Aguilar,5 Hemant Phatak2 1Texas Oncology, Houston, TX, USA; 2EMD Serono Research & Development Institute, Inc., Rockland, M

Externí odkaz: https://doaj.org/article/5081f6bb473447ba86148d4bd4bfc034

Zobrazit plný text záznamu

Akademický článek

Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives

Autor: Kongnakorn T, Bharmal M, Kearney M, Phatak H, Benedict A, Bhanegaonkar A, Galsky M

Publikováno v: ClinicoEconomics and Outcomes Research, Vol Volume 11, Pp 659-672 (2019)

Thitima Kongnakorn,1 Murtuza Bharmal,2 Mairead Kearney,3 Hemant Phatak,4 Agnes Benedict,5 Abhijeet Bhanegaonkar,4 Matthew Galsky6 1Evidence Synthesis, Modeling and Communication, Evidera, London, UK; 2Global Evidence and Value Development, EMD Serono

Externí odkaz: https://doaj.org/article/a05ffa0ad64d4ab9bc91f472eae8250d

Zobrazit plný text záznamu

Akademický článek

Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US

Autor: Bharmal M, Kearney M, Zheng Y, Phatak H

Publikováno v: ClinicoEconomics and Outcomes Research, Vol Volume 11, Pp 349-359 (2019)

Murtuza Bharmal,1 Mairead Kearney,1 Ying Zheng,2 Hemant Phatak21Global Evidence and Value Development, Merck Healthcare KGaA, Darmstadt, Germany; 2US Health Economics and Outcomes Research, EMD Serono, Inc, Rockland, MA, USAObjective: To estimate the

Externí odkaz: https://doaj.org/article/5ec3f3eb050f4570a86a4df0eb3a33d9

Zobrazit plný text záznamu